Antibody, Bioavailability and RNA - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Antibody

Bioavailability

RNA

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. Ensuring that the CPP can escape this endosomal compartment is crucial for its bioavailability and bioactivity properties.

Bioavailability

Bioavailability In-Vivo RNA In-Vitro

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

AUGUST 30, 2022

A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?

Trials

Trials Drug Delivery Drugs Gene

Cell-penetrating peptides as a delivery system for oligonucleotides

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

Stay Connected